Sonia Distante
- Chief Consultant; MD, PhD
- +47 230 71 092
Education
- 1999-2003: MD PhD, University of Oslo, Norway
- 1990-1996: Bachelor of Medicine and Chirurgy, University of Aberdeen, UK
- 1986-1990: BSc, Genetics (Honours), University of Aberdeen, UK
Affiliation
- Metabolomics & Metabolic Molecular Biology Group, Department of Medical Biochemistry, Oslo University Hospital - Rikshospitalet, Norway
Research Summary
Hemochromatosis and iron metabolism have been Dr. Distante's research interests since 1996, when the responsible mutated genes were discovered. During her PhD studies, she investigated the prevalence of these mutations in Norway, focusing on factors regulating their phenotypical expression. Her collaborative work on the evolution and origin of the mutations has suggested that they are thousands of years old. It is possible that Vikings contributed to their spread along the European coastal areas, where the mutations are most prevalent. Dr. Distante has been a member of the Joint Scientific Committee for Hemochomatosis International since 2015. Her efforts, along with those of other members, have resulted in several significant achievements, including the development of international guidelines for diagnosis and treatment and a consensus study on screening for hemochromatosis.
Work Experience
- 2004-to date: Oslo University Hospital - Rikshospitalet, Norway
- 2003-2004: Korle-Bu Teaching Hospital, Ghana
- 1999-2003: University of Oslo, Norway
- 1996-1998: Aker University Hospital, Norway
- 1995-1996: Aberdeen Royal Infirmary, UK
Links
NB: Visit our NEWS PAGE for the latest updates and our Gallery for group social events!
Publications 2018
Therapeutic recommendations in HFE hemochromatosis for p.Cys282Tyr (C282Y/C282Y) homozygous genotype
Hepatol. Int., 12 (2), 83-86
DOI 10.1007/s12072-018-9855-0
Effects of individualized nutrition after allogeneic hematopoietic stem cell transplantation following myeloablative conditioning; a randomized controlled trial
Clin. Nutr. ESPEN, 28, 59-66
DOI 10.1016/j.clnesp.2018.08.002
Publications 2016
Blood removal therapy in hereditary hemochromatosis induces a stress response resulting in improved genome integrity
Transfusion, 56 (6), 1435-1441
DOI 10.1111/trf.13588
Publications 2015
Bloodletting therapy in hemochromatosis: Does it affect trace element homeostasis?
J. Trace Elem. Med. Biol., 31, 225-229
DOI 10.1016/j.jtemb.2014.07.021
Publications 2012
A Man with Abdominal Pain: Enough Evidence for Surgery?
Clin. Chem., 58 (8), 1187-1190
DOI 10.1373/clinchem.2011.167015
Publications 2006
Genetic predisposition to iron overload: Prevalence and phenotypic expression of hemochromatosis-associated HFE-C282Y gene mutation
Scand. J. Clin. Lab. Invest., 66 (2), 83-100
DOI 10.1080/00365510500495616
Publications 2004
The origin and spread of the HFE-C282Y haemochromatosis mutation
Hum. Genet., 115 (4), 269-279
DOI 10.1007/s00439-004-1152-4
The origin and spread of the HFE-C282Y haemochromatosis mutation
In Human genetics, Springer International, Berlin, 115(2004)4, S. 269-79
BIBSYS 05190831x
Publications 2003
Genetic predisposition to iron overload: prevalence and phenotypic expression of hemochromatosis associated HFE-C282Y gene mutation
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 134, 1 b. (flere pag.)
BIBSYS 040850374, ISBN 82-8080-066-2
Tumor necrosis factor alpha and its promoter polymorphisms' role in the phenotypic expression of hemachromatosis
In Scandinavian journal of gastroenterology, Taylor & Francis, Basingstoke, 38(2003)8, s.871-7
BIBSYS 041707850
Tumour necrosis factor alpha and its promoter polymorphisms' role in the phenotypic expression of hemochromatosis
Scand. J. Gastroenterol., 38 (8), 871-877
DOI 10.1080/00365520310003444
Publications 2002
Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection
Liver, 22 (3), 269-275
DOI 10.1046/j.0106-9543.2002.01672.x
Raised serum ferritin predicts non-response to interferonand ribavirin treatment in patients with chronic hepatitis C-infection
In Journal of hepatology, Munksgaard, København, 36(2002)Suppl 1, s. 233
BIBSYS 03142631x
Publications 2001
Phenotypic expression of the HFE gene mutation (C282Y) among the hospitalised population - Reply
Gut, 49 (1), 156
Publications 2000
The clinical expression of hemochromatosis in Oslo, Norway - Excessive oral iron intake may lead to secondary hemochromatosis even in HFE C282Y mutation negative subjects
Scand. J. Gastroenterol., 35 (12), 1301-1307
The clinical expression of hemachromatosis in Oslo, Norway. Excessive oral iron intake may lead to secondary hemachromatosis even in the HFE C282Y mutation negative subjects
In Scandinavian journal of gastroenterology, Taylor & Francis, Basingstoke, 35(2000)nr 12, s. 1301-1307
BIBSYS 010706097
HFE gene mutation (C282Y) and phenotypic expression among a hospitalised population in a high prevalence area of haemochromatosis
Gut, 47 (4), 575-579
DOI 10.1136/gut.47.4.575
HFE gene mutation (C282Y) and phenotypic expression amonga hospitalised population in a high prevalence area of haemochromatosis
In Gut, British Medical Association, London, 47(2000)nr 4, s. 575-579
BIBSYS 010719873
Publications 1999
High prevalence of the hemochromatosis-associated Cys282Tyr HFE gene mutation in a healthy Norwegian population in the city of Oslo, and its phenotypic expression
Scand. J. Gastroenterol., 34 (5), 529-534
DOI 10.1080/003655299750026290